Followers | 237 |
Posts | 10817 |
Boards Moderated | 0 |
Alias Born | 07/17/2006 |
Sunday, November 23, 2014 9:36:27 AM
You are right. Without explaining why you are wrong, we are no better than the FDA or any authoritarian source who offers no rationale.
To begin with, inflammation is not a "symptom." Inflammation is a process, the result of the inflammatory system. Inflammation may have symptoms, classically, swelling, heat, redness, and pain. Inflammation may also be asymptomatic which is the case for most chronic degenerative disease including atherosclerosis.
The derivation of the term inflammation is actually closer to "in flame", or "on fire". Now where I believe you get off the tracks is you are convinced that the cause which triggers inflammation is the perpetrator of the damage. Consider a forest fire. If lightning, or a match, starts a forest fire, that does not mean that lightning or the match burned down all the trees. No, it was the fire that did the damage. Inflammation is the fire.
As in the example of a forest fire, the likely hood the lightning bolt will result in a forest fire depends on other factors, how dry the weather has been, winds, and even the oxygen content in the atmosphere.
In the same sense there are factors that influence the effects of inflammation in our bodies. The inflammatory system is not set at one level for all time. The inflammatory system can be set to different levels of sensitivity like a thermostat. If the sensitivity is set too high, then the inflammatory system can become an enemy, attacking our own tissues. The inflammatory system possesses the chemicals and the soldiers (leukocytes, macrophages, dendrocytes) to destroy any tissue in our body, or to trigger processes like platelet aggregation, that can shut off vital circulation.
Atherosclerotic CVD is an inflammatory disease, because the inflammatory system set too high and it is attacking our arteries. Please understand, our arteries are not being "clogged" up excess lipids, they are being attacked by the inflammatory system.
We are beginning to understand that diet plays an important role in determining the sensitivity of the inflammatory system. We know that arachidonic acid (AA) is highly pro inflammatory, and the EPA is a competitive inhibitor of AA. We know from population studies comparing japanese to americans who have the same LDL-C levels, that the japanese with AA/EPA ratios which are one seventh the level of americans, will have one seventh the risk of CVD. There is other confirming evidence that diet effects inflammation,,(see the amino acid starvation reaction, or T. Keller on halofuginone).
And finally..yes, inflammation is not all bad and is necessary for our survival in a hostile environment. The inflammatory system guards us against microbial infection, even in acne, Still the inflammatory system is like the gas we burn in our homes, useful for cooking and heat in the winter, but still with the potential to kill us. When the inflammatory system gets out of control, the case in chronic degenerative diseases then we correctly call them inflammatory diseases, and decreasing systemic inflammation is the key to controlling them.
":>) JL
Recent AMRN News
- Amarin Reports First Quarter 2024 Business Update and Financial Results • GlobeNewswire Inc. • 05/01/2024 11:00:00 AM
- Amarin Applauds HealthyWomen’s Citizen’s Petition Urging FDA To Take Further Action On Fenofibrate Prescribing in Patients at Risk of Cardiovascular Event • GlobeNewswire Inc. • 04/24/2024 06:00:01 PM
- Amarin Announces Results of Annual General Meeting of Shareholders • GlobeNewswire Inc. • 04/22/2024 12:00:25 PM
- Amarin to Report First Quarter 2024 Financial Results and Host Conference Call on May 1, 2024 • GlobeNewswire Inc. • 04/15/2024 12:00:00 PM
- Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24 • GlobeNewswire Inc. • 04/08/2024 12:00:00 PM
- New REDUCE-IT® Analyses Show VASCEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups • PR Newswire (Canada) • 04/08/2024 10:30:00 AM
- New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups • GlobeNewswire Inc. • 04/06/2024 07:30:00 PM
- Amarin Provides Update on VAZKEPA® (Icosapent Ethyl) Intellectual Property Portfolio in Europe • GlobeNewswire Inc. • 04/03/2024 12:00:00 PM
- Research Evaluating Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the American College of Cardiology’s (ACC) Annual Scientific Session & Expo • GlobeNewswire Inc. • 03/25/2024 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 03/04/2024 10:30:53 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 03/04/2024 01:00:24 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/29/2024 12:06:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/29/2024 12:05:56 PM
- Amarin Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update • GlobeNewswire Inc. • 02/29/2024 12:00:00 PM
- Amarin to Report Fourth Quarter and Full Year 2023 Financial Results and Host Conference on February 29, 2024 • GlobeNewswire Inc. • 02/15/2024 01:00:00 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 02/12/2024 01:00:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 09:31:50 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 09:30:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 09:30:12 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 09:30:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 09:30:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 09:30:11 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/26/2024 12:00:49 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/24/2024 09:31:21 PM
- Amarin Chairman & CEO Issue Letter to Shareholders • GlobeNewswire Inc. • 01/22/2024 12:30:00 PM
FEATURED NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM